The Problem With Predictions: A Cautionary Tale of Empirically Adjusting Apixaban Dosing With CarbamazepineNovel Teaching Points
Concomitant use of apixaban and carbamazepine (CBZ) is not recommended due to an anticipated reduction in apixaban concentration, although few case reports describe this interaction. We report a case of initiating apixaban 10 mg twice daily (BID), in a patient stabilized on CBZ 600 mg BID that was g...
Main Authors: | Ayush Chadha, David Lopaschuk, BSc, BSc(Pharm), PharmD, Margaret L. Ackman, BSc(Pharm), PharmD, Tammy J. Bungard, BSP, PharmD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-04-01
|
Series: | CJC Open |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589790X22000026 |
Similar Items
-
Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points
by: Tammy J. Bungard, BSP, PharmD, et al.
Published: (2020-09-01) -
Critical Analysis of Apixaban Dose Adjustment Criteria
by: Anh Vu PharmD, et al.
Published: (2021-06-01) -
Effect of New Evidence on Antithrombotic Therapies in Atrial Fibrillation Patients Who Undergo Percutaneous Coronary Intervention in Alberta, Canada
by: Theresa E. Eberhardt, PharmD, ACPR, et al.
Published: (2022-04-01) -
Evaluation of Apixaban in Patients With Antiphospholipid Syndrome: A Case Series and Review of Literature
by: Khalid Al Sulaiman SCC-CCP, BCCCP, BCNSP, MBA, et al.
Published: (2022-05-01) -
Community Pharmacy-Based Blood Pressure Screening in Newfoundland and Labrador, Canada for World Hypertension Day 2022: A Cross-Sectional Study
by: Tiffany A. Lee, BSc(Pharm), PharmD, PhD(c), et al.
Published: (2024-05-01)